Evaxion BiotechEVAX
About: Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Employees: 49
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 [Q3] → 10 (+2) [Q4]
0.46% more ownership
Funds ownership: 0.99% [Q3] → 1.45% (+0.46%) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
60% less capital invested
Capital invested by funds: $1.71M [Q3] → $682K (-$1.03M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 26% 1-year accuracy 52 / 203 met price target | 653%upside $14 | Buy Reiterated | 20 Feb 2025 |
Lake Street Thomas Flaten 44% 1-year accuracy 4 / 9 met price target | 223%upside $6 | Buy Maintained | 4 Feb 2025 |
Financial journalist opinion









